Positive Feedback as new NHS deals hook £200k
Feedback plc, a specialist clinical communication company in Cambridge, has won two 12-month contracts to provide its flagship product, Bleepa, across two NHS Trusts for an aggregate value of £200k.
The first contract follows a successful pilot and co-development on the platform over the last two years, representing Feedback’s first full-cycle realisation of its pilot-to-contract business model.
The second represents a renewal following the success of an initial one-year deal and at a higher value than the initial contract.
Feedback CEO Tom Oakley said: “We are delighted to see the value of Bleepa as a core clinical system recognised through the award of two customer contracts.
“Over the last year we have significantly grown the number of Bleepa users and it is good to see this growth recognised in the uplift in contract value achieved. These contracts are early evidence of the success of our 2019 strategic shift.”
Another company in the local life science Cluster – Cambridge Clinical Laboratories (CCL) – is making its bowel cancer screening test available to all in this Bowel Cancer Awareness Month.
Its FIT (Faecal Immunochemical Test) is currently used by the NHS in over 50’s to screen for bowel cancer. However more than 2,600 people under 50 are diagnosed each year in the UK and these individuals will be missed by the screening programme so diagnosis won’t come until they develop symptoms and go through the NHS pathway.
Bowel cancer is treatable and curable especially if diagnosed early. Nearly everyone survives bowel cancer if diagnosed at the earliest stage. However, this drops significantly as the disease develops. Early diagnosis saves lives. The impact of Covid-19 isn’t isolated to just those getting the virus. The NHS is struggling, with waiting times for cancer referral and treatment at record high.
With nearly 43,000 people diagnosed with bowel cancer every year this new availability of the FIT test could make a huge difference helping to improve screening and speed up diagnosis.
CCL, based in Milton, is a leading lab with an objective to bring new technologies for diagnostics to the UK.
CEO Dr Anthony Cooke says: “2020 threw a huge curveball for the world in the form of the Covid-19 pandemic, as a result cancer healthcare has been hugely impacted.
“The new tests we are launching will help to ease the pressure of the NHS and support patients to take more of a lead with their healthcare; we know our tests will improve the lives of many.”